APOGEE THERAPEUTICS INC (APGE) Fundamental Analysis & Valuation

NASDAQ:APGE • US03770N1019

Current stock price

82.89 USD
+0.86 (+1.05%)
At close:
82.89 USD
0 (0%)
Pre-Market:

This APGE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. APGE Profitability Analysis

1.1 Basic Checks

  • APGE had negative earnings in the past year.
  • APGE had a negative operating cash flow in the past year.
APGE Yearly Net Income VS EBIT VS OCF VS FCFAPGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 -50M -100M -150M -200M -250M

1.2 Ratios

  • With a decent Return On Assets value of -27.30%, APGE is doing good in the industry, outperforming 67.96% of the companies in the same industry.
  • The Return On Equity of APGE (-28.30%) is better than 76.89% of its industry peers.
Industry RankSector Rank
ROA -27.3%
ROE -28.3%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
APGE Yearly ROA, ROE, ROICAPGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 -5 -10 -15 -20 -25

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for APGE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APGE Yearly Profit, Operating, Gross MarginsAPGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. APGE Health Analysis

2.1 Basic Checks

  • There is no outstanding debt for APGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
APGE Yearly Shares OutstandingAPGE Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M 50M
APGE Yearly Total Debt VS Total AssetsAPGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 109.81 indicates that APGE is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 109.81, APGE belongs to the best of the industry, outperforming 98.45% of the companies in the same industry.
  • There is no outstanding debt for APGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 109.81
ROIC/WACCN/A
WACCN/A
APGE Yearly LT Debt VS Equity VS FCFAPGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 26.57 indicates that APGE has no problem at all paying its short term obligations.
  • The Current ratio of APGE (26.57) is better than 96.70% of its industry peers.
  • APGE has a Quick Ratio of 26.57. This indicates that APGE is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of APGE (26.57) is better than 96.70% of its industry peers.
Industry RankSector Rank
Current Ratio 26.57
Quick Ratio 26.57
APGE Yearly Current Assets VS Current LiabilitesAPGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. APGE Growth Analysis

3.1 Past

  • APGE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -28.38%.
EPS 1Y (TTM)-28.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, APGE will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.30% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-14.98%
EPS Next 2Y-16.77%
EPS Next 3Y-17.13%
EPS Next 5Y9.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
APGE Yearly Revenue VS EstimatesAPGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 1B 2B 3B
APGE Yearly EPS VS EstimatesAPGE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. APGE Valuation Analysis

4.1 Price/Earnings Ratio

  • APGE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year APGE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APGE Price Earnings VS Forward Price EarningsAPGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APGE Per share dataAPGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • APGE's earnings are expected to decrease with -17.13% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.77%
EPS Next 3Y-17.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. APGE Dividend Analysis

5.1 Amount

  • APGE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

APGE Fundamentals: All Metrics, Ratios and Statistics

APOGEE THERAPEUTICS INC

NASDAQ:APGE (4/30/2026, 8:00:02 PM)

Premarket: 82.89 0 (0%)

82.89

+0.86 (+1.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)03-02
Earnings (Next)05-11
Inst Owners117.29%
Inst Owner Change-0.18%
Ins Owners1.86%
Ins Owner Change-8.84%
Market Cap6.14B
Revenue(TTM)N/A
Net Income(TTM)-255.84M
Analysts85.22
Price Target119.2 (43.81%)
Short Float %17.42%
Short Ratio10.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.39%
Min EPS beat(2)4.31%
Max EPS beat(2)8.47%
EPS beat(4)3
Avg EPS beat(4)8.8%
Min EPS beat(4)-2.92%
Max EPS beat(4)25.36%
EPS beat(8)4
Avg EPS beat(8)2.24%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.06%
PT rev (3m)13.04%
EPS NQ rev (1m)0.49%
EPS NQ rev (3m)0.08%
EPS NY rev (1m)3.86%
EPS NY rev (3m)4.05%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.79
P/tB 6.79
EV/EBITDA N/A
EPS(TTM)-4.22
EYN/A
EPS(NY)-4.85
Fwd EYN/A
FCF(TTM)-3.14
FCFYN/A
OCF(TTM)-3.07
OCFYN/A
SpS0
BVpS12.21
TBVpS12.21
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -27.3%
ROE -28.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 362.98%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 26.57
Quick Ratio 26.57
Altman-Z 109.81
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.45%
EPS Next Y-14.98%
EPS Next 2Y-16.77%
EPS Next 3Y-17.13%
EPS Next 5Y9.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-31.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28.12%
EBIT Next 3Y-18.47%
EBIT Next 5Y12.64%
FCF growth 1Y-34.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.88%
OCF growth 3YN/A
OCF growth 5YN/A

APOGEE THERAPEUTICS INC / APGE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of APOGEE THERAPEUTICS INC (APGE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to APGE.


What is the valuation status of APOGEE THERAPEUTICS INC (APGE) stock?

ChartMill assigns a valuation rating of 0 / 10 to APOGEE THERAPEUTICS INC (APGE). This can be considered as Overvalued.


What is the profitability of APGE stock?

APOGEE THERAPEUTICS INC (APGE) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for APGE stock?

The Earnings per Share (EPS) of APOGEE THERAPEUTICS INC (APGE) is expected to decline by -14.98% in the next year.